Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2023; 14(12): 1721-1737
Published online Dec 15, 2023. doi: 10.4239/wjd.v14.i12.1721
Published online Dec 15, 2023. doi: 10.4239/wjd.v14.i12.1721
Analysis of the management and therapeutic performance of diabetes mellitus employing special target
Hong-Yan Sun, Xiao-Yan Lin, Department of Endocrine and Metabolic Diseases, Yantaishan Hospital, Yantai 264003, Shandong Province, China
Author contributions: Sun HY and Lin XY contributed equally to this study. Both authors reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yan Lin, MD, PhD, Professor, Department of Endocrine and Metabolic Diseases, Yantaishan Hospital, No.10087, Keji Avenue, Laishan District, Yantai City, Shandong Province, 264003, China. lxyfvn776@126.com
Received: July 24, 2023
Peer-review started: July 24, 2023
First decision: August 17, 2023
Revised: August 31, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: December 15, 2023
Peer-review started: July 24, 2023
First decision: August 17, 2023
Revised: August 31, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: December 15, 2023
Core Tip
Core Tip: Diabetes mellitus (DM) is a chronic metabolic condition characterized by hyperglycemia. Major contributing factors are insufficient insulin secretion, insulin resistance, or both. Global diabetes prevalence has risen from 4% to 6.4% in the past 30 years and may reach 430 million in the future. Age, obesity, and a sedentary lifestyle exacerbate the disease. Developing safe and effective therapies is crucial. Medications like glucagon-like peptide-1 agonists, thiazolidinediones, and others have been available for over a decade. However, clinical observations suggest ongoing research. This review focuses on insulin regulation targets for potentially more efficient and secure diabetes treatments.